ARTIN Bioscience

Artin Bioscience is a biotechnology company based in Irvine, California, dedicated to advancing the next generation of cancer immunotherapies. The company leverages its proprietary ARTIN platform, which stands for Antigen-specific Receptor-mediated Targeted Immuno-Nanoparticle, to deliver immune-modulating payloads specifically to tumor cells and the surrounding microenvironment. Its lead program, ARTIN-001, is a targeted STING agonist designed to stimulate a robust innate and adaptive immune response against solid tumors while reducing systemic side effects. By transforming 'cold' tumors into 'hot' ones, Artin Bioscience seeks to improve outcomes for patients who are non-responsive to current checkpoint inhibitors. The company's approach aims to provide a safer and more effective alternative to systemic immunotherapy through precision localized delivery.